Safety, Pharmacokinetics, and Predicted Lung Concentration of a Novel SARS-CoV2 Mpro Inhibitor in Healthy Volunteers

Abstract: International Conference on Emerging Infectious Diseases 2022 Poster and Oral Presentation Abstracts Emerging Infectious Diseases is providing access to these abstracts on behalf of the ICEID 2022 program committee (http://www.iceid.org), which performed peer review. ICEID is organized by the Centers for Disease Control and Prevention and Task Force for Global Health, Inc. Emerging Infectious Diseases has not edited or proofread these materials and is not responsible for inaccuracies or omissions. All information is subject to change. Comments and corrections should be brought to the attention of the authors. Suggested citation: Authors. Title [abstract]. International Conference on Emerging Infectious Diseases 2022 poster and oral presentation abstracts. Emerg Infect Dis. 2022 Sep [date cited]. http://www.cdc.gov/EID/pdfs/ICEID2022.pdf Page 1 of 297 Monday, August 8, 2022 Poster Session 1 Abstracts 12:30 PM – 1:30 PM Grand Hall COVID-19 and SARS-CoV-2 Poster 1. Anti-SARS-Cov-2 Antibody in COVID-19 Positive Patients: Scope and Limitation R. Raihan1, S.A. Hassan Abdullah2, S. Islam3, M. Murshed4, G. D. Harun5, T. Aktar4, N. Jubaida6, M. Ul Anwar7 1 US Bangla Medical College, Dhaka Bangladesh, 2 South Asia Field Epidemiology & Technology Network (SAFETYNET), Bangladesh, 3American Society of Microbiology (ASM), Bangladesh, 4 Holy Family Red Crescent Medical College, Dhaka, Bangladesh, 5Icddrb, Dhaka, Bangladesh, 6Armed Forces Institute of Pathology Bangladesh, 7Dhaka University, Bangladesh Background: The ongoing pandemic of coronavirus disease 2019 (COVID-19) has shattered the entire world with 4.55 million deaths. In order to develop proper containment strategy, there is a pressing need to develop insights about the real proportions of SARS-CoV-2 infected persons among total population of any country or community. Although the role of antibody assay system has been of no help for diagnosis of SARS-CoV-2 infection, the utility of antibody testing for epidemiological purposes remains an open field. Methods: In this study, we used three different commercial SARS-CoV-2 antibody kits to develop insights about the utility of these kits in Bangladesh perspective. We selected 161 PCR-confirmed SARS-CoV-2-infected patients and checked their SARS-CoV-2 antibody presence at 3 time points - 5th, 8th and 14th day after primary diagnosis of the infection. Results: Among the 161 participants, 83% were male, majority (80%) aged below 50 years and 68.83% were symptomatic. On the day 5th and 8th of PCR positivity, 47.0%-58.0% and 66.5%- 83.0% patients’ antibody (IgM/IgG) was positive respectively, which reached between 82.6%- 93.0% on day 14th after the COVID-19 diagnosis. Conclusions: We observed higher antibody positivity rate along with the time irrespective of the kits used. Results imply that antibody kits might be useful for epidemiological studies. This can also be used to detect the infection at the later stage of the disease process after two weeks when PCR or antigen test is negative. Poster 2. Implementation of an Adaptive Event-based Surveillance System through a Network of Drug Dispensing Outlets to Enhance Detection of COVID-19 Cases in Communities in Dar es Salaam, Tanzania, 2020 H.L. Mohamed1, D. Faini1, L. Ngailo2, C. Munishi1, R. Mutayoba2, R. Mpembeni1, M. Mponela3, M.F. Jalloh3, P. Mmbuji3, W. Gatei3, L. Subi4, E. Kwesi4, M. Bakari1, J.M. Mghamba1,4 1 Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania,..